SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jdv12177-sup-0001-TableS1-S2-FigureS1-S2.docWord document153K

Table S1. SF-36 Domain Scores and Mean Changes From Baseline by Treatment Group at Week 12

Table S2. SF-36 Domain Scores and Mean Changes From Baseline by Treatment Group at Week 52

Figure S1. Proportion of patients with minimum clinically important difference improvements for individual Short Form 36 Health Survey domains at week 12. aStatistically significant difference (P < 0.001) between briakinumab and placebo at the 5% level.

Figure S2. Proportion of patients with minimum clinically important difference improvements for individual Short Form 36 Health Survey domains at week 52. aStatistically significant difference (P ≤ 0.001) between briakinumab and placebo at the 5% level. bSignificant difference (P = 0.007) between briakinumab and placebo at the 5% level. cSignificant difference (P < 0.001) between briakinumab every 4 weeks and briakinumab every 12 weeks.

jdv12177-sup-0002-FigureS1.tiffTIFF image21K 
jdv12177-sup-0003-FigureS2.tiffTIFF image436K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.